ALLO News and Press, Allogene Therapeutics Inc. From 06/04/21

ASCO Posters Detail Results from ALLO-501 ALPHA and ALLO-501A ALPHA2 Trials in Non-Hodgkin Lymphoma and Safety and PK/PD Data of ALLO-647 with Flu/Cy Across the ALPHA, ALPHA2 and UNIVERSAL Studies Results from Most Recent Data Discussed at Allogene’s CD19 Forum Demonstrate...

Shares of Allogene Therapeutics Inc. (NASDAQ:ALLO) traded today at $24.41, breaking its 52-week low. Approximately 254,000 shares have changed hands today, as compared to an average 30-day volume of 1.5 million shares. In the past 52 weeks, shares of Allogene Therapeutics Inc. have trade...

ASCO is a very important cancer clinical research meeting. We identified 70 smid-cap cancer companies presenting updated clinical data at ASCO21. 13 companies' value increased by over 10% with ASCO21 info release thus far. PDSB is an early ASCO21 mover, with its HPV vaccine ca...

Shares of Allogene Therapeutics Inc. (NASDAQ:ALLO) traded today at $24.66, breaking its 52-week low. This new low was reached on below average trading volume as 254,000 shares traded hands, while the average 30-day volume is approximately 1.2 million shares. Over the past year, Allogene ...

Allogene (ALLO) plans to initiate a pivotal trial of its off-the-shelf CAR T therapy ALLO-501A by the end of the year.The disclosure was made May 20 as the company reported positive early-stage data on several CAR T candidates it will present at next month's American Society of Clinical Oncol...

Merck downgraded on Organon spinoff impactArgus has downgraded Merck (MRK) from buy to hold ahead of next month's spinoff of the Organon division and the implications it might have on the bottom line.Analyst David Toung writes that the spinoff will at least initially lower Merck's operating m...

SOUTH SAN FRANCISCO, Calif., May 20, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to participate in f...

Virgin Galactic Holdings (SPCE) +21% after test flight scheduled for May 22VistaGen Therapeutics (VTGN) +15% after Baird calls stock 'significantly undervalued'.Allogene Therapeutics (ALLO) +13% on positive early-stage data for CAR T candidates in blood cancer.PDS Biotechnology...

Allogene Therapeutics (ALLO) announced positive data from two Phase 1 clinical trials for ALLO-501 and ALLO-501A in relapsed/refractory non-Hodgkin lymphoma ((NHL)). The experimental anti-CD19 allogeneic CAR T therapies are developed in partnership with Servier.The data will be...

ALLO-501 ALPHA Trial Produced Durable Complete Responses (CR) with Longest Ongoing CR at 15 Months in Both Large B Cell Lymphoma (LBCL) and Follicular Lymphoma (FL) Overall Response Rate (ORR) of 75% and CR Rate of 50% Across Histologies in CAR T Naïve Patients, on Par with Dat...